Biocon Limited and Zentiva have celebrated receiving a frontrunning approval for generic liraglutide after the UK Medicines and Healthcare Products Regulatory Agency endorsed the partners’ 6mg/ml solution for injection in pre-filled pen.
Biocon And Zentiva Hail Milestone Liraglutide Approval In UK
Partners Plan For ‘Expeditious’ Launch After Claiming Leading Position On GLP-1
Biocon and Zentiva have celebrated the “first generic liraglutide approved in a major regulated/ICH market” after an endorsement from the UK’s MHRA.
More from Products
More from Generics Bulletin
• By
As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.
• By
Coherus has officially marked its exit from biosimilars by completing the divestment of its Udenyca pegfilgrastim franchise. Meanwhile, buyer Accord BioPharma has set out how it expects to benefit not only from a growing asset but also from the Coherus personnel that have moved over.
• By
Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.